SFSIG
PTLA

San Francisco Sentry Investment Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

San Francisco Sentry Investment Group’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-150
Closed -$5K – 917
2018
Q1 		$5K Hold
150
– – ﹤0.01% 772
2017
Q4 		$7K Hold
150
– – ﹤0.01% 728
2017
Q3 		$8K Buy
+150
New +$8.81K ﹤0.01% 687

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ZCI
Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

San Francisco Sentry Investment Group's PTLA Position: Q2 2018 in Review

San Francisco Sentry Investment Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2018, closing a stake of 150 shares — an estimated $5K sold.

San Francisco Sentry Investment Group first reported a position in PTLA in Q3 2017 and held it in 3 quarters. The position peaked at $8K in Q3 2017. 204 funds tracked by Wall St. Rank hold PTLA as of Q2 2018.

  • San Francisco Sentry Investment Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 150 Portola Pharmaceuticals, Inc. shares in Q2 2018, an estimated $5K.
  • San Francisco Sentry Investment Group first reported a position in Portola Pharmaceuticals, Inc. in Q3 2017 and held it in 3 quarters.
  • San Francisco Sentry Investment Group's Portola Pharmaceuticals, Inc. position peaked at $8K in Q3 2017.
  • 204 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2018.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2018, filed 6 Aug 2018.